We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+9.82%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$838M
AUM Growth
-$14.9M
Cap. Flow
-$32.9M
Cap. Flow %
-3.93%
Top 10 Hldgs %
68.16%
Holding
36
New
1
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$41.1M
2
XFOR icon
X4 Pharmaceuticals
XFOR
+$3.88M
3
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$3.7M
4
ANNX icon
Annexon
ANNX
+$1.95M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$162K

Top Sells

Rank Stock Value
1
DVAX
Dynavax Technologies
DVAX
+$39.1M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$23.1M
3
RACB
Research Alliance Corp. II Class A Common Stock
RACB
+$9.8M
4
ARYD
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
+$6.87M
5
PANA
Panacea Acquisition Corp. II Class A Ordinary Shares
PANA
+$4.88M

Sector Composition

Rank Sector Weight
1 Healthcare 97.33%
2 Financials 1.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
$138M 16.45%
4,831,307
– –
NUVL
2
DELISTED
Nuvalent
NUVL
$66.6M 7.95%
3,428,014
– –
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$58.6M 6.99%
346,547
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.23B
$57.3M 6.84%
3,000,000
– –
DVAX
5
DELISTED
Dynavax Technologies
DVAX
$56.5M 6.75%
5,415,000
-3,000,000
-36% -$39.1M
EQRX
6
DELISTED
EQRx, Inc. Common Stock
EQRX
$49.5M 5.91%
10,003,573
– –
CRNX icon
7
Crinetics Pharmaceuticals
CRNX
$8.93B
$45.3M 5.41%
2,305,558
– –
THRD
8
DELISTED
Third Harmonic Bio
THRD
$43.3M 5.16%
+2,280,082
New +$41.1M
AMLX icon
9
Amylyx Pharmaceuticals
AMLX
$2.5B
$28.8M 3.44%
1,023,214
-925,000
-47% -$23.1M
RPID icon
10
Rapid Micro Biosystems
RPID
$86.2M
$27.2M 3.25%
8,434,560
– –
TVRD
11
Tvardi Therapeutics
TVRD
$22M
$24.8M 2.96%
73,541
– –
PHVS icon
12
Pharvaris
PHVS
$2.46B
$24.4M 2.91%
3,180,601
– –
NRIX icon
13
Nurix Therapeutics
NRIX
$2.66B
$23.8M 2.84%
1,822,883
– –
ANNX icon
14
Annexon
ANNX
$868M
$22.3M 2.66%
3,601,926
+360,298
+11% +$1.95M
TSVT
15
DELISTED
2seventy bio
TSVT
$20.5M 2.45%
1,408,901
– –
PTGX icon
16
Protagonist Therapeutics
PTGX
$9.6B
$19.1M 2.27%
2,260,572
– –
SVRA icon
17
Savara
SVRA
$1.16B
$18M 2.15%
11,622,598
– –
CCCC icon
18
C4 Therapeutics
CCCC
$401M
$14.4M 1.72%
1,642,210
– –
AVIR icon
19
Atea Pharmaceuticals
AVIR
$401M
$14.1M 1.69%
2,485,638
– –
XFOR icon
20
X4 Pharmaceuticals
XFOR
$430M
$10.9M 1.3%
212,981
+112,330
+112% +$3.88M
ACAD icon
21
Acadia Pharmaceuticals
ACAD
$5.05B
$9.99M 1.19%
610,523
+10,000
+2% +$162K
MRNS
22
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$9.52M 1.14%
1,431,058
– –
XLO icon
23
Xilio Therapeutics
XLO
$60.8M
$8.16M 0.97%
200,387
– –
SYRS
24
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$6.97M 0.83%
1,082,404
+455,962
+73% +$3.7M
TNGX icon
25
Tango Therapeutics
TNGX
$4.38B
$6.96M 0.83%
1,921,790
– –
1
2

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q3 2022 Portfolio in Review

As of Q3 2022, Bain Capital Life Sciences Investors held 36 positions worth $838M, down 1.8% from $853M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $32.9M in Q3 2022, closing 3 positions and reducing 2 holdings. Its most notable exit was Research Alliance Corp. II Class A Common Stock, an estimated $9.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Financials.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Third Harmonic Bio worth $43.3M.

  • Bain Capital Life Sciences Investors's largest Q3 2022 buy was Third Harmonic Bio: 2,280,082 shares worth $43.3M.
  • Bain Capital Life Sciences Investors added most to X4 Pharmaceuticals in Q3 2022, an estimated $3.88M increase.
  • Bain Capital Life Sciences Investors's biggest Q3 2022 reduction was Dynavax Technologies, cutting an estimated $39.1M.
  • Bain Capital Life Sciences Investors fully exited Research Alliance Corp. II Class A Common Stock in Q3 2022, selling an estimated $9.8M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 68% of its $838M portfolio in Q3 2022.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 3 in Q3 2022.
  • Bain Capital Life Sciences Investors's portfolio value fell 1.8% quarter-over-quarter to $838M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2022, filed 14 Nov 2022.